METHODS	Patients with stage IIIB/IV nonsquamous non-small-cell lung cancer randomly received cetuximab ( 400 mg/m initially , 250 mg/m weekly thereafter ) plus bevacizumab ( 15 mg/kg ) for six cycles combined with paclitaxel ( 200 mg/m ) and carboplatin ( area under the curve 6 ) for either six cycles ( six-cycle arm ) or the first three cycles ( three-cycle arm ) ( one cycle = 3 weeks ) .\